Spark Therapeutics’ mission is to unleash the power of gene therapy to accelerate the transformation of healthcare. We have created a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Learn more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRD), liver diseases such as haemophilia and neurodegenerative diseases.

 

Code: SPARK-2022

Funding entity:SPARK

Competitive: No

Center: GENyO

Time of implementation: 01/12/2023 – 01/02/2024

Principal Investigator: Dr. Francisco Javier Molina Estévez 

More information: https://sparktx.com/

 

Other international projects